Sufferers with hemophilia A or B with inhibitors have a decrease annualized bleeding price with concizumab than with no prophylaxis, in line with a section 3 research printed on-line Aug. 31 within the New England Journal of Medication.
Tadashi Matsushita, M.D., Ph.D., from Nagoya College Hospital in Japan, and colleagues evaluated the protection and efficacy of concizumab in sufferers with hemophilia A or B with inhibitors. As a part of the explorer7 section 3 trial, contributors had been randomly assigned to obtain no prophylaxis for not less than 24 weeks (group 1; 19 sufferers) or to obtain concizumab prophylaxis for not less than 32 weeks (group 2; 33 sufferers), or they had been nonrandomly assigned to obtain concizumab prophylaxis for not less than 24 weeks (teams 3 and 4; 81 sufferers).
The researchers discovered that the estimated imply annualized bleeding price in group 1 was 11.8 episodes versus 1.7 episodes in group 2 (price ratio, 0.14; P “Concizumab represents a novel, subcutaneous therapy possibility in sufferers with hemophilia A or B with inhibitors that may probably enhance long-term outcomes,” the authors write.
Tadashi Matsushita et al, Part 3 Trial of Concizumab in Hemophilia with Inhibitors, New England Journal of Medication (2023). DOI: 10.1056/NEJMoa2216455
H. Marijke van den Berg et al, Hemostasis—A Balancing Act, New England Journal of Medication (2023). DOI: 10.1056/NEJMe2304535
Copyright © 2023 HealthDay. All rights reserved.
Concizumab could also be efficient prophylaxis for hemophilia A or B with inhibitors (2023, September 3)
retrieved 3 September 2023
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.